ArticleChemical biology & drug design2025
Anti-Inflammatory Compounds From Roots of Heracleum sphondylium subsp. cyclocarpum.
Article in Chemical biology & drug design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Heracleum sphondylium subsp. cyclocarpum (K. Koch) P.H. Davis from Heracleum L. genus, which is one of the widest genera of the Apiaceae family and known as "Hogweed or Tavşancılotu". This genus has a variety of traditional uses, including treating gastrointestinal, cardiovascular, gynecological, and cognitive disorders, skin problems, rheumatism, and inflammation. In particular, these plants are commonly used for inflammatory diseases. This research aimed to examine in detail the anti-inflammatory properties of Heracleum sphondylium subsp. cyclocarpum roots. Bioactivity-guided fractionation was used to isolate the active compounds. Carrageenan- and prostaglandin E2-induced inflammation models were employed to test the activity. Dichloromethane and methanolic extracts of the plant material were tested for activity and found to be effective in inhibiting inflammation. The subfractions obtained by column chromatography were further evaluated for their activities. The active fractions were used to obtain responsible compounds by using semipreparative HPLC. Five coumarin derivatives were isolated and identified as heraclenol (1), byakangelicin (2), heraclenol-3″-O-β-glucoside (3), byakangelicin-3″-O-β-glucoside (4), and meranzin hydrate III (5). The isolated compounds were investigated for their anti-inflammatory activities, and heraclenol-3″-O-β-glucoside was found to inhibit the carrageenan and prostaglandin E2-induced edema significantly compared to the control group and have higher activity than the extracts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.